Modified DNA Plasmid Kanamycin Promoter Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
DNA vaccines, such as those using the pVR1012 plasmid, face challenges with plasmid instability and copy-number heterogeneity, which affect the expression of target antigens and the induction of an efficient immune response, limiting their effectiveness in clinical settings.
Innovation Solution
A DNA plasmid with a kanamycin resistance gene featuring a less effective promoter, like the P1 promoter, or with a transposon inserted between the kanamycin resistance gene promoter and translation initiation, resulting in decreased kanamycin resistance expression, leading to higher plasmid yields and stability, is developed. This formulation is combined with a pharmaceutically acceptable carrier for enhanced antigen delivery and immune response stimulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a strong kanamycin resistance gene promoter is used in the plasmid, then kanamycin resistance expression is enhanced, but plasmid stability and replication rates decrease
Solution Approach 1:
The patent applies parameter changes by modifying the promoter strength of the kanamycin resistance gene. Specifically, it uses a weaker promoter (such as the P1 promoter or a mutated promoter with reduced activity) instead of a strong promoter, thereby changing the expression level parameter to achieve optimal plasmid stability and replication without complete loss of selection pressure.
2Reliability
If a strong kanamycin resistance gene promoter is used in the plasmid, then kanamycin resistance expression is enhanced, but plasmid replication rates decrease
Solution Approach 1:
The patent modifies the promoter strength parameter to balance kanamycin resistance expression with plasmid replication. By using a weaker promoter, the metabolic burden on the bacterial host is reduced, allowing for higher plasmid replication rates while maintaining sufficient resistance for selection purposes.
3Reliability
If the original pVR1012 plasmid design is used, then kanamycin resistance is maintained, but plasmid yields and stability are reduced
Solution Approach 1:
The patent changes the promoter parameter in the kanamycin resistance gene to achieve higher plasmid yields. The modified promoter reduces excessive expression that interferes with plasmid replication, thereby increasing the quantity of plasmid produced while maintaining adequate resistance for bacterial selection.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to compositions and methods to improve expression of exogenous polypeptides, such as an antigen, epitope, immunogen, peptide or polypeptide of interest. More particularly, the present invention provides for DNA plasmids with increased expression and stability in compositions and methods useful for DNA vaccines.